BidaskClub cut shares of Aclaris Therapeutics (NASDAQ:ACRS) from a hold rating to a sell rating in a research note released on Thursday morning.
A number of other research firms also recently commented on ACRS. Cantor Fitzgerald reaffirmed a buy rating and set a $50.00 price objective on shares of Aclaris Therapeutics in a report on Tuesday, September 26th. Zacks Investment Research raised shares of Aclaris Therapeutics from a hold rating to a buy rating and set a $31.00 price objective for the company in a report on Tuesday, October 10th. Three equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The company has a consensus rating of Hold and a consensus price target of $39.20.
Aclaris Therapeutics (ACRS) traded up $0.14 during midday trading on Thursday, reaching $24.40. 319,680 shares of the company’s stock traded hands, compared to its average volume of 258,089. The firm has a market cap of $752.37, a price-to-earnings ratio of -11.30 and a beta of 1.96. Aclaris Therapeutics has a 52 week low of $21.32 and a 52 week high of $33.25.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.23. The company had revenue of $0.68 million during the quarter, compared to analyst estimates of $2.00 million. equities research analysts forecast that Aclaris Therapeutics will post -2.59 earnings per share for the current year.
Several large investors have recently added to or reduced their stakes in ACRS. Citigroup Inc. lifted its holdings in shares of Aclaris Therapeutics by 171.8% during the 2nd quarter. Citigroup Inc. now owns 4,313 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 2,726 shares during the period. Legal & General Group Plc lifted its holdings in shares of Aclaris Therapeutics by 98.3% during the 2nd quarter. Legal & General Group Plc now owns 5,254 shares of the biotechnology company’s stock worth $142,000 after acquiring an additional 2,605 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of Aclaris Therapeutics during the 3rd quarter worth about $142,000. Voya Investment Management LLC bought a new position in shares of Aclaris Therapeutics during the 2nd quarter worth about $247,000. Finally, Trexquant Investment LP bought a new position in shares of Aclaris Therapeutics during the 3rd quarter worth about $247,000. 92.02% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/21/aclaris-therapeutics-acrs-cut-to-sell-at-bidaskclub.html.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.